Company intelligence / Profile preview

Notogen

Ownership: Private
Development stage: Preclinical

Overview

Notogen’s lead candidate, NTG‑101, is a patented protein-based injectable biologic that has shown efficacy in preclinical models for protecting spinal discs from degeneration, promoting regeneration, and reducing discogenic pain. It is non-surgical and non-cellular. The company is advancing toward IND-enabling studies with the goal of entering clinical trials[1][5].

Therapeutic areas: NeurologyRheumatology
Modalities: Protein-based biologics (non-cellular)
Industry: Biotech

Drug pipeline

1 asset

NTG-101

Preclinical

Beyond the preview

Go deeper on Notogen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Notogen.

Explore the full profile